Critical role of Kupffer cell CR3 (CD11b/CD18) in the clearance of IgM-opsonized erythrocytes or soluble β-glucan

Immunopharmacology

Volumn 46, Issue 1, 2000, Pages 39-54

  Yan, Jun ^a   Větvička, Václav ^a   Xia, Yu ^a   Hanikýřová, Margareta ^a   Mayadas, Tanya N ^b   Ross, Gordon D ^a  

^a University of Louisville School of Medicine   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Biological response modifier; C3 receptor; Clearance; Complement; Liver; Macrophage

Indexed keywords

BETA GLUCAN; CD18 ANTIGEN; COMPLEMENT COMPONENT C3 RECEPTOR; COMPLEMENT COMPONENT C3B RECEPTOR; GLYCOPROTEIN P 15095; IMMUNOGLOBULIN M; POLYSACCHARIDE; RECEPTOR SUBTYPE;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; ERYTHROCYTE; FEMALE; IMMUNOCYTOCHEMISTRY; ISOTOPE LABELING; KNOCKOUT MOUSE; KUPFFER CELL; MOUSE; NONHUMAN; OPSONIZATION; ORGAN DISTRIBUTION; PERITONEUM MACROPHAGE; PHAGOCYTOSIS; PLASMA CLEARANCE; PRIORITY JOURNAL;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD18; CHROMIUM RADIOISOTOPES; ERYTHROCYTES; FEMALE; GLUCANS; IMMUNOGLOBULIN M; IODINE RADIOISOTOPES; KINETICS; KUPFFER CELLS; MACROPHAGE-1 ANTIGEN; MICE; MICE, INBRED BALB C; MICE, KNOCKOUT; OPSONIN PROTEINS; ORGAN SPECIFICITY; RECEPTORS, COMPLEMENT 3B; ZYMOSAN;

EID: 0342615080     PISSN: 01623109     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0162-3109(99)00157-5     Document Type: Article

References (82)

1. Abe S., Takahashi K., Tsubouchi J., Aida K., Yamazaki M., Mizuno D. Different local therapeutic effects of various polysaccharides on MH134 hepatoma in mice and its relation to inflammation induced by the polysaccharides. Gann. 75:1984;459-465.
2. Adachi Y., Okazaki M., Ohno N., Yadomae T. Enhancement of cytokine production by macrophages stimulated with (1→3)-β-D-glucan, Grifolan (GRN), isolated from Grifola frondosa. Biol. Pharm. Bull. 17:1994;1554-1560.
3. Adachi Y., Ohno N., Yadomae T. Activation of murine Kupffer cells by administration with gelforming (1→3)-β-D-glucan from Grifola frondosa. Biol. Pharm. Bull. 21:1998;278-283.
4. Atkinson J.P., Frank M.M. Studies on the in vivo effects of antibody. Interaction of IgM antibody and complement in the immune clearance and destruction of erythrocytes in man. J. Clin. Invest. 54:1974;339-348.
5. Atkinson J.P., Frank M.M. The effect of Bacillus Calmette-Guerin-induced macrophage activation on the in vivo clearance of sensitized erythrocytes. J. Clin. Invest. 53:1974;1742-1749.
6. Atkinson J.P., Oglesby T.J., White D., Adams E.A., Liszewski M.K. Separation of self from non-self in the complement system: a role for membrane cofactor protein and decay accelerating factor. Clin. Exp. Immunol. 86(1):1991;27-30. Suppl.
7. Benacerraf, B., 1964. Functions of the Kupffer cells. In: Rouiller, C. (Ed.), The Liver. Morphology, Biochemistry, Physiology, Vol. 2. Academic Press, New York, pp. 37-62.
8. Bouwens L., Baekeland M., De Zanger R., Wisse E. Quantitation, tissue distribution and proliferation kinetics of Kupffer cells in normal rat liver. Hepatology. 6:1986;718-722.
9. Brown D.L., Lachmann P.J., Dacie J.V. The in vivo behaviour of complement-coated red cells: studies in C6-deficient, C3-depleted, and normal rabbits. Clin. Exp. Immunol. 7:1970;401-422.
10. Cain J.A., Newman S.L., Ross G.D. Role of complement receptor type three and serum opsonins in the neutrophil response to yeast. Complement Inflammation. 4:1987;75-86.
11. Cheong J.-J., Hahn M.G. A specific, high-affinity binding site for the hepta-β-glucoside elicitor exists in soybean membranes. Plant Cell. 3:1991;137-147.
12. Chihara G. Recent progress in immunopharmacology and therapeutic effects of polysaccharides. Dev. Biol. Stand. 77:1992;191-197.
13. Cosio E.G., Popperl H., Schmidt W.E., Ebel J. High-affinity binding of fungal β-glucan fragments to soybean (Glycine max L.) microsomal fractions and protoplasts. Eur. J. Biochem. 175:1988;309-315.
14. Coxon A., Rieu P., Barkalow F.J., Askari S., Sharpe A.H., Von Andrian U.H., Arnaout M.A., Mayadas T.N. A novel role for the β2 integrin CD11b/CD18 in neutrophil apoptosis: a homeostatic mechanism in inflammation. Immunity. 5:1996;653-666.
15. Crofton R.W., Diesselhoff-den Dulk M.M., van Furth R. The origin, kinetics, and characteristics of the Kupffer cells in the normal steady state. J. Exp. Med. 148:1978;1-17.
16. Davies K.A., Erlendsson K., Beynon H.L.C., Peters A.M., Steinsson K., Valdimarsson H., Walport M.J. Splenic uptake of immune complexes in man is complement-dependent. J. Immunol. 151:1993;3866-3873.
17. Ehlenberger A.G., Nussenzweig V. The role of membrane receptors for C3b and C3d in phagocytosis. J. Exp. Med. 145:1977;357-371.
18. Fang Y.F., Xu C.G., Fu Y.X., Holers V.M., Molina H. Expression of complement receptors 1 and 2 on follicular dendritic cells is necessary for the generation of a strong antigen-specific IgG response. J. Immunol. 160:1998;5273-5279.
19. 4). Eur. J. Immunol. 15:1985;1192-1197.
20. Fraker P.J., Speck J.C. Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6,-tetrachloro-3a,6a-diphenylglycoluril. Biochem. Biophys. Res. Commun. 80:1978;849-857.
21. Frank M.M., Schreiber A.D., Atkinson J.P., Jaffe C.J. NIH conference. Pathophysiology of immune hemolytic anemia. Ann. Intern. Med. 87:1977;210-222.
22. Fujimoto S. Clinical efficacies of schizophyllan (SPG) on advanced gastric cancer. Nippon Geka Gakkai Zasshi. 90:1989;1447-1450.
23. Hamuro J., Sasaki T., Chihara G., Amano M. Radioautographic study on the distribution of a polysaccharide with antitumor activity in mice. Gann. 61:1970;589-591.
24. Hinglais N., Kazatchkine M.D., Mandet C., Appay M.-D., Bariety J. Human liver Kupffer cells express CR1, CR3, and CR4 complement receptor antigens. An immunohistochemical study. Lab. Invest. 61:1989;509-514.
25. Hogg N., Takacs L., Palmer D.G., Selvendran Y., Allen C. The p150,95 molecule is a marker of human mononuclear phagocytes: comparison with expression of Class II molecules. Eur. J. Immunol. 16:1986;240-248.
26. Huber H., Fudenberg H.H. The interaction of monocytes and macrophages with immunoglobulin and complement. Ser. Haematol. 3:1970;160-175.
27. Iznaga-Escobar N., Torres A.L., Morales M.A., Ramos S.M., Rodriguez M.N., Perez R.R. Technetium-99m-antiepidermal growth factor-receptor antibody in patients with tumors of epithelial origin: Part II. Pharmacokinetics and clearances. J. Nucl. Med. 39:1998;1918-1927.
28. Jaffe C.J., Atkinson J.P., Frank M.M. The role of complement in the clearance of cold agglutinin-sensitized erythrocytes in man. J. Clin. Invest. 58:1976;942-949.
29. Kim Y.-U., Kinoshita T., Molina H., Hourcade D., Seya T., Wagner L.M., Holers V.M. Mouse complement regulatory protein Crry/p65 uses the specific mechanisms of both human decay-accelerating factor and membrane cofactor protein. J. Exp. Med. 181:1995;151-159.
30. Kimura Y., Tojima H., Fukase S., Takeda K. Clinical evaluation of sizofilan as assistant immunotherapy in treatment of head and neck cancer. Acta Oto-Laryngol. (Stockholm). 511:1994;192-195. Suppl.
31. Kinoshita T., Lavoie S., Nussenzweig V. Regulatory proteins for the activated third and fourth components of complement (C3b and C4b) in mice: II. Identification and properties of complement receptor type 1 (CR1). J. Immunol. 134:1985;2564-2570.
32. Kinoshita T., Takeda J., Hong K., Kozono H., Sakai H., Inoue K. Monoclonal antibodies to mouse complement receptor type 1 (CR1). Their use in a distribution study showing that mouse erythrocytes and platelets are CR1-negative. J. Immunol. 140:1988;3066-3072.
33. Kirschfink M., Knoblauch K., Roelcke D. Activation of complement by cold agglutinins. Infusionsther. Transfusionsmed. 21:1994;405-409.
34. Kruisbeek, A.M., 1996. In vitro assays for mouse lymphocyte function. In: Coligan, J.E., Kruisbeek, A.M., Margulies, D.H., Shevach, E.M., Strober, W. (Eds.), Current Protocols in Immunology. John Wiley & Sons, Inc., New York, pp. 3.0.5-3.1.5.
35. Lee S.H., Crocker P., Gordon S. Macrophage plasma membrane and secretory properties in murine malaria. Effects of Plasmodium yoelii blood-stage infection on macrophages in liver, spleen, and blood. J. Exp. Med. 163:1986;54-74.
36. Lepay D.A., Nathan C.F., Steinman R.M., Murray H.W., Cohn Z.A. Murine Kupffer cells. Mononuclear phagocytes deficient in the generation of reactive oxygen intermediates. J. Exp. Med. 161:1985;1079-1096.
37. Ljungman A.G., Leanderson P., Tagesson C. (1→3)-β-D-glucan stimulates nitric oxide generation and cytokine mRNA expression in macrophages. Environ. Toxicol. Pharmacol. 5:1998;273-281.
38. Loegering D.J. Kupffer cell complement receptor clearance function and host defense. Circ. Shock. 20:1986;321-333.
39. Mantovani B., Rabinovitch M., Nussenzweig V. Phagocytosis of immune complexes by macrophages. Different roles of the macrophage receptor sites for complement (C3) and for immunoglobulin (IgG). J. Exp. Med. 135:1972;780-792.
40. Martin B.K., Weis J.H. Murine macrophages lack expression of the Cr2-145 (CR2) and Cr2-190 (CR1) gene products. Eur. J. Immunol. 23:1993;3037-3042.
41. Matsuoka H., Seo Y., Wakasugi H., Saito T., Tomoda H. Lentinan potentiates immunity and prolongs the survival time of some patients. Anticancer Res. 17:1997;2751-2755.
42. McHale J.F., Harari O.A., Marshall D., Haskard D.O. Vascular endothelial cell expression of ICAM-1 and VCAM-1 at the onset of eliciting contact hypersensitivity in mice: evidence for a dominant role of TNF-α J. Immunol. 162:1999;1648-1655.
43. Metlay J.P., Witmer-Pack M.D., Agger R., Crowley M.T., Lawless D., Steinman R.M. The distinct leukocyte integrins of mouse spleen dendritic cells as identified with new hamster monoclonal antibodies. J. Exp. Med. 171:1990;1753-1771.
44. Miura N.N., Ohno N., Aketagawa J., Tamura H., Tanaka S., Yadomae T. Blood clearance of (1→3)-β-D-glucan in MRL lpr/lpr mice. FEMS Immunol. Med. Microbiol. 13:1996;51-57.
45. 3. J. Clin. Invest. 82:1988;640-651.
46. Newman S.L., Mikus L.K. Deposition of C3b and iC3b onto particulate activators of the human complement system. Quantitation with monoclonal antibodies to human C3. J. Exp. Med. 161:1985;1414-1431.
47. Nilsson Ekdahl K., Lööf L., Nilsson U.R., Nilsson B. An improved method to study complement receptor-mediated function of the fixed macrophage system in vivo. Vox Sang. 61:1991;47-52.
48. Quigg R.J., Holers V.M. Characterization of rat complement receptors and regulatory proteins: CR2 and Crry are conserved, and the C3b receptor of neutrophils and platelets is distinct from CR1. J. Immunol. 155:1995;1481-1488.
49. Quigg R.J., Alexander J.J., Lo C.F., Lim A., He C., Holers V.M. Characterization of C3-binding proteins on mouse neutrophils and platelets. J. Immunol. 159:1997;2438-2444.
50. Rosenthal L.A., Sutterwala F.S., Kehrli M.E., Mosser D.M. Leishmania major human macrophage interactions: cooperation between Mac-1 (CD11b/CD18) and complement receptor type 1 (CD35) in promastigote adhesion. Infect. Immun. 64:1996;2206-2215.
51. Ross, G.D., 1981. Detection of complement receptors and Fc receptors on macrophages. In: Herscowitz, H.B., Holden, H.T., Bellanti, J.A., Ghaffar, A. (Eds.), Manual of Macrophage Methodology. Marcel Dekker, New York, pp. 209-227.
52. Ross, G.D., 1986. Opsonization and membrane complement receptors. In: Ross, G.D. (Ed.), Immunobiology of the Complement System, An Introduction for Research and Clinical Medicine. Academic Press, Orlando, pp. 87-114.
53. Ross, G.D., 1998. Complement receptors. In: Delves, P.J., Roitt, I.M. (Eds.), Encyclopedia of Immunology, 2nd edn. Academic Press, London, pp. 629-634.
54. Ross G.D., Reed W. The leukocyte integrin and complement receptor CR3 (CD11b/CD18) has specificity for C3dg, as well as for iC3b. FASEB J. 6:1992;A2013.
55. Ross, G.D., Winchester, R.J., 1980. Methods for enumerating lymphocyte populations. In: Rose, N.R., Friedman, H. (Eds.), Manual of Clinical Immunology. American Society for Microbiology, Washington, DC, pp. 213-228.
56. 1 cofactor activity. J. Immunol. 129:1982;2051-2060.
57. Ross G.D., Newman S.L., Lambris J.D., Devery-Pocius J.E., Cain J.A., Lachmann P.J. Generation of three different fragments of bound C3 with purified factor I or serum: II. Location of binding sites in the C3 fragments for factors B and H, complement receptors, and bovine conglutinin. J. Exp. Med. 158:1983;334-352.
58. 1, C3b-receptors) in patients with systemic lupus erythematosus and other diseases involving autoantibodies and/or complement activation. J. Immunol. 135:1985;2005-2014.
59. Ross G.D., Reed W., Dalzell J.G., Becker S.E., Hogg N. Macrophage cytoskeleton association with CR3 and CR4 regulates receptor mobility and phagocytosis of iC3b-opsonized erythrocytes. J. Leukocyte Biol. 51:1992;109-117.
60. Ross G.D., Větvička V., Yan J., Xia Y., Vetvickova J. Therapeutic intervention with complement and β-glucan in cancer. Immunopharmacology. 42:1999;61-74.
61. Sakagami Y., Mizoguchi Y., Shin T., Seki S., Kobayashi K., Morisawa S., Yamamoto S. Effects of an anti-tumor polysaccharide, schizophyllan, on interferon γ and interleukin 2 production by peripheral blood mononuclear cells. Biochem. Biophys. Res. Commun. 155:1988;650-655.
62. Sakurai T., Ohno N., Yadomae T. Changes in immune mediators in mouse lung produced by administration of soluble (1→3)-β-D-glucan. Biol. Pharm. Bull. 17:1994;617-622.
63. Schreiber A.D., Frank M.M. Role of antibody and complement in the immune clearance and destruction of erythrocytes: II. Molecular nature of IgG and IgM complement-fixing sites and effects of their interaction with serum. J. Clin. Invest. 51:1972;583-589.
64. Schreiber A.D., Frank M.M. Role of antibody and complement in the immune clearance and destruction of erythrocytes: I. In vivo effects of IgG and IgM complement-fixing sites. J. Clin. Invest. 51:1972;575-582.
65. Sherwood E.R., Williams D.L., McNamee R.B., Jones E.L., Browder I.W., Di Luzio N.R. Soluble glucan and lymphokine-activated killer (LAK) cells in the therapy of experimental hepatic metastases. J. Biol. Response Modif. 7:1988;185-198.
66. Shevach, E.M., 1992. Immunofluorescence and cell sorting. In: Colligan, J.E., Kruisbeek, A.M., Margulies, D.H., Shevach, E.M., Strober, W. (Eds.), Current Protocols in Immunology. John Wiley & Sons, Inc., New York, pp. 5.0.1-5.8.8.
67. Shimizu Y., Teshima H., Chen J.-T., Fujimoto I., Hasumi K., Masubuchi K. Augmentative effect of sizofiran on the immune functions of regional lymph nodes in patients with cervical cancer. Acta Obstet. Gynaecol. Jpn. 43:1991;581-588.
68. 125I -tyraminyl cellobiose Immunopharmacology. 21:1991;149-158.
69. Smedsrød B., Pertoft H., Eggertsen G., Sundström C. Functional and morphological characterization of cultures of Kupffer cells and liver endothelial cells prepared by means of density separation in Percoll, and selective substrate adherence. Cell Tissue Res. 241:1985;639-649.
70. Suda M., Ohno N., Hashimoto T., Koizumi K., Adachi Y., Yadomae T. Kupffer cells play important roles in the metabolic degradation of a soluble anti-tumor (1→3)-β-D-glucan, SSG, in mice. FEMS Immunol. Med. Microbiol. 15:1996;93-100.
71. Sveinbjornsson B., Rushfeldt C., Seljelid R., Smedsrød B. Inhibition of establishment and growth of mouse liver metastases after treatment with interferon gamma and β-1,3-D-glucan. Hepatology. 27:1998;1241-1248.
72. Takahashi K., Kozono Y., Waldschmidt T.J., Berthiaume D., Quigg R.J., Baron A., Holers V.M. Mouse complement receptors type 1 (CR1; CD35) and type 2 (CR2; CD21) - expression on normal B cell subpopulations and decreased levels during the development of autoimmunity in MRL/lpr mice. J. Immunol. 159:1997;1557-1569.
73. Thornton B.P., Větvička V., Pitman M., Goldman R.C., Ross G.D. Analysis of the sugar specificity and molecular location of the β-glucan-binding lectin site of complement receptor type 3 (CD11b/CD18). J. Immunol. 156:1996;1235-1246.
74. Větvička V., Thornton B.P., Ross G.D. Soluble β-glucan polysaccharide binding to the lectin site of neutrophil or NK cell complement receptor type 3 (CD11b/CD18) generates a primed state of the receptor capable of mediating cytotoxicity of iC3b-opsonized target cells. J. Clin. Invest. 98:1996;50-61.
75. Větvička V., Thornton B.P., Wieman T.J., Ross G.D. Targeting of NK cells to mammary carcinoma via naturally occurring tumor cell-bound iC3b and β-glucan-primed CR3 (CD11b/CD18). J. Immunol. 159:1997;599-605.
76. Williams D.L., Sherwood E.R., McNamee R.B., Jones E.L., Di Luzio N.R. Therapeutic efficacy of glucan in a murine model of hepatic metastatic disease. Hepatology. 5:1985;198-206.
77. Winchester, R.J., Ross, G.D., 1986. Methods for enumerating cell populations by surface markers using conventional microscopy. In: Rose, N.R., Friedman, H., Fahey, J.L. (Eds.), Manual of Clinical Laboratory Immunology. American Society for Microbiology, Washington, DC, pp. 212-225.
78. Xia, Y., Ross, G.D., 1999. CR3. In: Morley, B.J., Walport, M.J. (Eds.), Complement FactsBook. Academic Press, London, pp. 188-197.
79. Xia Y., Větvička V., Yan J., Hanikyrova M., Mayadas T.N., Ross G.D. The β-glucan-binding lectin site of mouse CR3 (CD11b/CD18) and its function in generating a primed state of the receptor that mediates cytotoxic activation in response to iC3b-opsonized target cells. J. Immunol. 162:1999;2281-2290.
80. Yan, J., Větvička, V., Xia, Y., Coxon, A., Carroll, M.C., Mayadas, T.N., Ross, G.D., 1999. β-Glucan, a "specific" biological response modifier that uses antibodies to target tumors for recognition by CR3 (CD11b/CD18). J. Immunol., in press.
81. Yoshida M., Roth R.I., Grunfeld C., Feingold K.R., Levin J. Soluble (1→3)-β-D-glucan purified from Candida albicans: biologic effects and distribution in blood and organs in rabbits. J. Lab. Clin. Med. 128:1996;103-114.
82. Yoshida T., Saeki T., Aoyama Y., Okudaira T., Okada T., Funasaka S. Treatment of head and neck cancers with BRMs - prolongation of survival. Biotherapy. 10:1997;115-120.